Research ArticleOriginal Article

A four-gene signature-derived risk score for glioblastoma: prospects for prognostic and response predictive analyses

Mianfu Cao, Juan Cai, Ye Yuan, Yu Shi, Hong Wu, Qing Liu, Yueliang Yao, Lu Chen, Weiqi Dang, Xiang Zhang, Jingfang Xiao, Kaidi Yang, Zhicheng He, Xiaohong Yao, Yonghong Cui, Xia Zhang and Xiuwu Bian
Cancer Biology & Medicine August 2019, 16 (3) 595-605; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0277

References

  1. 1.↵
    2. Wen PY,
    3. Reardon DA.
    Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016; 12: 69–70.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Tanaka S,
    3. Louis DN,
    4. Curry WT,
    5. Batchelor TT,
    6. Dietrich J.
    Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013; 10: 14–26.
    OpenUrlPubMed
  3. 3.↵
    2. Malkki H.
    Neuro-oncology: novel biomarkers for high-grade astrocytoma. Nat Rev Neurol. 2014; 10: 121.
    OpenUrl
  4. 4.↵
    2. Xu YY,
    3. Gao P,
    4. Sun Y,
    5. Duan YR.
    Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med. 2015; 12: 223–37.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Filbin MG,
    3. Suvà ML.
    Gliomas genomics and epigenomics: arriving at the start and knowing it for the first time. Annu Rev Pathol. 2016; 11: 497–521.
    OpenUrl
  6. 6.↵
    2. Kim J,
    3. Lee IH,
    4. Cho HJ,
    5. Park CK,
    6. Jung YS,
    7. Kim Y, et al.
    Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015; 28: 318–28.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Wang QH,
    3. Hu BL,
    4. Hu X,
    5. Kim H,
    6. Squatrito M,
    7. Scarpace L, et al.
    Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017; 32: 42–56.
    OpenUrlCrossRefPubMed
  8. 8.
    2. Anwar SL,
    3. Wulaningsih W,
    4. Watkins J.
    Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs. Cancer Biol Med. 2017; 14: 387–95.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Shi Y,
    3. Ping YF,
    4. Zhou WC,
    5. He ZC,
    6. Chen C,
    7. Bian BSJ, et al.
    Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for Tumour growth. Nat Commun. 2017; 8: 15080.
    OpenUrlCrossRef
  10. 10.↵
    2. Love MI,
    3. Huber W,
    4. Anders S.
    Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Bolstad BM,
    3. Irizarry RA,
    4. Åstrand M,
    5. Speed TP.
    A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19: 185–93.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Irizarry RA,
    3. Hobbs B,
    4. Collin F,
    5. Beazer-Barclay YD,
    6. Antonellis KJ,
    7. Scherf U, et al.
    Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4: 249–64.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Ritchie ME,
    3. Phipson B,
    4. Wu D,
    5. Hu YF,
    6. Law CW,
    7. Shi W, et al.
    limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e4.
  14. 14.↵
    2. Subramanian A,
    3. Tamayo P,
    4. Mootha VK,
    5. Mukherjee S,
    6. Ebert BL,
    7. Gillette MA, et al.
    Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102: 15545–50.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Merico D,
    3. Isserlin R,
    4. Stueker O,
    5. Emili A,
    6. Bader GD.
    Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010; 5: e13984.
  16. 16.↵
    2. Tan J,
    3. Liu M,
    4. Zhang JY,
    5. Yao YL,
    6. Wang YX,
    7. Lin Y, et al.
    Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma. J Pathol. 2018; 245: 160–71.
    OpenUrl
  17. 17.↵
    2. Li Y,
    3. He ZC,
    4. Zhang XN,
    5. Liu Q,
    6. Chen C,
    7. Zhu Z, et al.
    Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1. Cancer Lett. 2018; 416: 66–74.
    OpenUrlCrossRef
  18. 18.↵
    2. Wang Z,
    3. Wang B,
    4. Shi Y,
    5. Xu C,
    6. Xiao HL,
    7. Ma LN, et al.
    Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. 2015; 34: 1407–19.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Yan H,
    3. Parsons DW,
    4. Jin GL,
    5. McLendon R,
    6. Rasheed BA,
    7. Yuan WS, et al.
    IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765–73.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Reifenberger G,
    3. Wirsching HG,
    4. Knobbe-Thomsen CB,
    5. Weller M.
    Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017; 14: 434–52.
    OpenUrl
  21. 21.↵
    2. Subramanian J,
    3. Simon R.
    What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol. 2010; 7: 327–34.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    2. Caffarel MM,
    3. Coleman N.
    Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014; 232: 386–90.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Pathiraja TN,
    3. Nayak SR,
    4. Xi YX,
    5. Jiang SM,
    6. Garee JP,
    7. Edwards DP, et al.
    Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014; 6: 229ra41.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    2. Tang XL,
    3. Ding BX,
    4. Hua Y,
    5. Chen H,
    6. Wu T,
    7. Chen ZQ, et al.
    HOXC10 promotes the metastasis of human lung adenocarcinoma and indicates poor survival outcome. Front Physiol. 2017; 8: 557.
    OpenUrl
  25. 25.↵
    2. Brown CO,
    3. Schibler J,
    4. Fitzgerald MP,
    5. Singh N,
    6. Salem K,
    7. Zhan FH, et al.
    Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leuk Res. 2013; 37: 963–9.
    OpenUrl
  26. 26.↵
    2. Kaler P,
    3. Prasad R.
    Molecular cloning and functional characterization of novel zinc transporter rZip10 (Slc39a10) involved in zinc uptake across rat renal brush-border membrane. Am J Physiol Renal Physiol. 2007; 292: F217–29.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords